PMC5488110_01
Patient flow diagram
40487_2017_40_Fig1_HTML.jpg
PMC5488110_02_40487_2017_40_Fig1_HTML.jpg
Fig1
Of the 10 patients who switched from degarelix, three received the leuprorelin acetate implant before radiotherapy as neoadjuvant therapy and the seven men who received it as adjuvant therapy are still receiving the implant (Fig. 1).
PMC5488110_02
Patient flow diagram
40487_2017_40_Fig1_HTML.jpg
PMC5488110_02_40487_2017_40_Fig1_HTML.jpg
Fig1
Of the 10 patients who switched from degarelix, three received the leuprorelin acetate implant before radiotherapy as neoadjuvant therapy and the seven men who received it as adjuvant therapy are still receiving the implant (Fig. 1).
PSA levels of 10 patients measured before and after switching from an LHRH antagonist to an LHRH agonist
40487_2017_40_Fig2_HTML.jpg
PMC5488110_02_40487_2017_40_Fig2_HTML.jpg
Fig2
PSA measurement, 1-6 months, mean 2.2 +- 1.6 (SD)]. PSA levels were comparable or reduced from those measured prior to switching, showing that efficacy was not compromised (Fig. 2).